This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| IGF1R | |
|---|---|
| Name | Insulin-like growth factor 1 receptor |
| Organism | Human |
| Uniprot | P08069 |
| Location | Plasma membrane |
| Length | 1367 aa |
IGF1R The insulin-like growth factor 1 receptor is a transmembrane tyrosine kinase receptor central to signaling networks that control cell proliferation, survival, and metabolism. Discovered through biochemical and genetic work in laboratories associated with Cold Spring Harbor Laboratory, Massachusetts Institute of Technology, and Harvard Medical School, the receptor links extracellular peptide ligands to intracellular cascades studied across models used at Stanford University and University of Cambridge. IGF1R research intersects clinical programs at Mayo Clinic, Johns Hopkins Hospital, and Dana-Farber Cancer Institute because of its implications for cancer, growth disorders, and aging.
The receptor is a heterotetramer composed of two extracellular alpha subunits and two transmembrane beta subunits produced from a single precursor via proteolytic processing, a structural organization characterized by crystallographers at European Molecular Biology Laboratory and groups at Max Planck Institute. The ectodomain contains L1, cysteine-rich, L2, and fibronectin type III domains analogous to domains defined in studies at Scripps Research Institute and University of Oxford. The intracellular portion bears a split tyrosine kinase domain homologous to kinases characterized by Kenneth Kendrew-era structural biology and later refined by teams at Cold Spring Harbor Laboratory. Autophosphorylation on conserved tyrosines within the activation loop promotes downstream docking, a mechanism elucidated by investigators linked to Howard Hughes Medical Institute funding and collaborations with National Institutes of Health.
Canonical ligands include insulin-like growth factor 1 and insulin-like growth factor 2, identified in biochemical screens at Rockefeller University and University of Cambridge, while hybrid receptors formed with the insulin receptor were characterized in studies associated with Imperial College London. Ligand binding triggers receptor dimerization and activation of canonical pathways such as the phosphoinositide 3-kinase (PI3K)–AKT axis and the RAS–RAF–MEK–ERK cascade, signaling modules also implicated in work from Ludwig Institute for Cancer Research and Cold Spring Harbor Laboratory. Adapter proteins including IRS family members and SHC mediate signaling transitions, concepts explored in research at University of California, San Francisco and Yale University. Cross-talk with receptors studied at Stanford University School of Medicine and modulation by phosphatases discovered at Institut Pasteur further diversify pathway outputs.
IGF1R mediates mitogenic and anti-apoptotic effects in diverse tissues investigated in models developed at Wistar Institute and Monash University. In muscle, bone, and nervous system contexts examined by groups at University of California, Los Angeles and University of Toronto, receptor signaling promotes hypertrophy, osteogenesis, and neuronal survival. Endocrine regulation involving glands studied at Mayo Clinic and Cleveland Clinic integrates hepatic production of ligands with peripheral receptor action, a systemic axis characterized by epidemiological cohorts from Framingham Heart Study and intervention trials at National Institutes of Health.
Genetic and developmental studies at University of Cambridge and Harvard Medical School demonstrated that receptor activity is crucial for prenatal and postnatal growth trajectories, with knockout models produced at Cold Spring Harbor Laboratory and EMBL showing perinatal lethality or growth retardation. Studies of growth disorders in clinics such as Great Ormond Street Hospital and Boston Children's Hospital linked receptor pathway perturbations to short stature and overgrowth syndromes, paralleling molecular genetics work at Wellcome Sanger Institute. Evolutionary comparisons using specimens from Smithsonian Institution collections and palaeobiological analyses at University of Chicago have traced conserved motifs across vertebrates.
Aberrant signaling through the receptor is implicated in oncogenesis in cancers treated at Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, where overexpression or activation correlates with poor prognosis in cohorts studied at European Society for Medical Oncology. Metabolic conditions evaluated in trials at Karolinska Institute and University of São Paulo show links between receptor cross-talk and insulin resistance. Mutations and imprinting effects influencing receptor pathways are relevant to syndromes documented by clinical geneticists at Royal College of Physicians and registries curated by Orphanet. Neurological degeneration models from Salk Institute investigations implicate changes in receptor signaling in neurodegenerative disease progression.
Small molecules, monoclonal antibodies, and ligand traps developed in pharmaceutical programs at Pfizer, Novartis, AstraZeneca, and Roche have targeted the receptor or its ligands, with clinical trials conducted under protocols approved by Food and Drug Administration and European Medicines Agency. Dual IGF1R/insulin receptor inhibitors and selective antagonists evaluated at National Cancer Institute demonstrated mixed efficacy and metabolic toxicity, prompting combination strategies tested at Stanford Cancer Institute and Fred Hutchinson Cancer Center. Biomarker-driven trials designed at Dana-Farber Cancer Institute and precision medicine consortia at Broad Institute aim to stratify patients based on pathway activation.
The gene locus was mapped using linkage analysis techniques refined at Wellcome Trust and sequencing initiatives at Human Genome Project contributors including Broad Institute and Sanger Institute. Tissue-specific expression profiles derived from consortia such as GTEx and proteomic atlases produced by ProteomeXchange reveal regulated transcription and alternative splicing reported in studies at University of Pennsylvania and Cold Spring Harbor Laboratory. Epigenetic regulation, microRNA targeting, and imprinting mechanisms affecting ligand expression were characterized in labs at Max Planck Institute for Molecular Genetics and Institut Curie.
Category:Receptors